Evidence map›Paper›PMID 36059037›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2023

Soluble factors in malignant ascites promote the metastatic adhesion of gastric adenocarcinoma cells.

Luai Al-Marzouki, Vivian S Stavrakos, Sanjima Pal, Betty Giannias, France Bourdeau, Roni Rayes, Nicholas Bertos, Sara Najmeh, Jonathan D Spicer, Jonathan Cools-Lartigue and 3 more

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Luai Al-Marzouki *Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Vivian S Stavrakos *Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Sanjima PalResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Betty GianniasResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
France BourdeauResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Roni RayesResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Nicholas BertosResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Sara NajmehResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jonathan D SpicerResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Jonathan Cools-LartigueResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Swneke D BaileyResearch Institute of the McGill University Health Centre, Montreal, QC, Canada.
Lorenzo FerriResearch Institute of the McGill University Health Centre, Montreal, QC, Canada. lorenzo.ferri@mcgill.ca.
Veena SangwanResearch Institute of the McGill University Health Centre, Montreal, QC, Canada. veena.sangwan@mcgill.ca.ORCID http://orcid.org/0000-0002-0951-5997
McGill University Health Centre · CAMontreal General Hospital · CA

Funding

DOD Peer Reviewed Cancer Research Program CA200572The Cancer Research Society 24234The Cancer Research Society 24381The Cancer Research Society 25320
6 · The paper itself

Abstract

backgroundAdenocarcinoma of the proximal stomach is the fastest rising malignancy in North America. It is commonly associated with peritoneal accumulation of malignant ascites (MA), a fluid containing cancer and inflammatory cells and soluble proteins. Peritoneal metastasis (PM) is the most common site of gastric cancer (GC) progression after curative-intent surgery and is the leading cause of death among GC patients. METHODS/

resultsUsing a panel of gastric adenocarcinoma cell lines (human: MKN 45, SNU-5; murine: NCC-S1M), we demonstrate that prior incubation of GC cells with MA results in a significant (> 1.7-fold) increase in the number of cells capable of adhering to human peritoneal mesothelial cells (HPMC) (p < 0.05). We then corroborate these findings using an ex vivo PM model and show that MA also significantly enhances the ability of GC cells to adhere to strips of human peritoneum (p < 0.05). Using a multiplex ELISA, we identify MIF and VEGF as consistently elevated across MA samples from GC patients (p < 0.05). We demonstrate that agents that block the effects of MIF or VEGF abrogate the ability of MA to stimulate the adhesion of GC cells to adhere to human peritoneum and promote both ex vivo and in vivo metastases.

conclusionAgents targeting MIF or VEGF may be relevant to the treatment or prevention of PM in GC patients.

Indexed as

AdenocarcinomaPeritoneal NeoplasmsStomach NeoplasmsAnimalsAscitesCell Line, TumorHumansMiceVascular Endothelial Growth Factor AVascular Endothelial Growth Factor AGastric cancerMacrophage migration inhibitory factor (MIF)Malignant ascitesPeritoneal metastasisVascular endothelial growth factor (VEGF)

Identifiers

PMID36059037
OpenAlexW4294567955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.